DrugSupplement
Palforzia clinical trials
Also written Peanut protein and DBV712.
- studies test it
- 12
- open now
- 0
- in phase 3
- 4
- first study started
- 2004
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2021 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 1
- Phase 2
- 2
- Phase 3
- 4
- No phase
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 7
DBV Technologies (5) · Auburn University (3) · Texas A&M University (1) · Scott Sicherer (1) · Stanford University (1) · University of North Carolina, Chapel Hill (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Palforzia is read from its arms, and is right about nine times in ten.
Testing it · 12
- Peanut Sip Feeding ProtocolCompletedNot applicableTexas A&M UniversityNCT06693544Written as Peanut protein
- Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)Active, not recruitingPhase 3DBV TechnologiesNCT07003919Written as DBV712 250 mcg
- Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of AgeActive, not recruitingPhase 3DBV TechnologiesNCT05741476Written as DBV712
- Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut AllergyCompletedPhase 3DBV TechnologiesNCT02636699Written as Viaskin Peanut 250mcg
- Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young ChildrenCompletedPhase 3DBV TechnologiesNCT03859700Written as DBV712 250 mcg
- Immune Basis and Clinical Implications of Threshold-based Phenotypes of Peanut AllergyCompletedPhase 2Scott SichererNCT03907397Written as Peanut Protein
- Peanut Protein Supplementation to Prevent Muscle Atrophy and Improve Recovery Following Total Knee ArthroplastyTerminatedNot applicableAuburn UniversityNCT04294563Written as Peanut Protein Powder
- Peanut Protein Supplementation to Augment Muscle Growth and Improve Markers of Muscle Quality and Health in Young AdultsCompletedNot applicableAuburn UniversityNCT04707963Written as Peanut protein powder
- Peanut Protein Supplementation to Augment Muscle Growth and Improve Markers of Muscle Quality and Health in Older AdultsCompletedNot applicableAuburn UniversityNCT04015479Written as Peanut Protein Powder
- The Peanut Oral Immunotherapy Study: Safety, Efficacy and DiscoveryCompletedPhase 2Stanford UniversityNCT02103270Written as Peanut Protein 300 mg
- A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic SubjectsCompletedPhase 1DBV TechnologiesNCT03352726Written as DBV712 IHRP
- Oral Peanut Immunotherapy for Peanut Allergic PatientsCompletedEarly Phase 1University of North Carolina, Chapel HillNCT01891136Written as Peanut protein
Codes
What other systems call Palforzia · ClinicalTrials.gg INT002132
- MeSH (NLM) C000731750PalforziaOne source NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731750 | Palforzia | One source NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.